# 2026 *Pricing Principles Report*

## Reporting of U.S. Pricing Actions

In the United States, medicines represent about *10% of total healthcare spending*—a meaningful but relatively small share compared to other sectors of healthcare. We acknowledge our role in limiting our contribution to U.S. healthcare spending growth and preserving the sustainability of our healthcare system.

**Our approach to pricing actions for existing medicines balances our ambition to chase the miracles of science, patients' access to the medicines they need, government policies, and evolving marketplace trends.**

The guiding principle for any list price actions taken during fiscal year 2025 was to maintain a level consistent with our responsible pricing approach.

Additionally, in alignment with our commitment to price transparency, Sanofi has pledged to disclose additional background annually if price actions trigger a mandatory supplemental rebate under the Inflation Reduction Act (IRA) of 2022.

## A Look Back: *Our 2025 U.S. Report Card*

In 2025, Sanofi increased the price of **42** of its **72** prescription medicines and vaccines in line with our Pricing Principles.

Of these, we increased the list price of Sarclisa (isatuximab-irfc) in 2025, resulting in nominal penalties under the mandatory rebate program created by the IRA.

Sarclisa first *launched in 2020* to treat patients with relapsed or refractory multiple myeloma in combination with pomalidomide and dexamethasone, and the *2024 approval*, based on positive results from the IMROZ phase 3 study in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma not eligible for transplant, enhanced its value. These pricing actions align with the enhanced clinical value of the therapy.